TP53 mutations, which are known to occur in the synovium in rheumatoid arthritis [37, 38], upregulate IL-6 levels [142, 143], perhaps mediating the inflammation of arthritis and explaining the efficacy of tocilizumab in this condition. The gene discussed is IL6; the disease is arthritic joint disease.